Free tool
FAERS Monitor: Mavenclad
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022561 or its brand name (Mavenclad, Cladribine). Reports on generic versions are filed under their own applications.
Reports
9,967
Serious
7,443
75% of reports
Hospitalization
2,318
Death reported
717
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- fatigue848
- headache713
- lymphocyte count decreased507
- multiple sclerosis relapse494
- nausea437
- pneumonia418
- white blood cell count decreased376
- off label use339
- drug ineffective309
- pyrexia294
- urinary tract infection288
- multiple sclerosis270
- asthenia252
- lymphopenia238
- febrile neutropenia218
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 24 |
| 2005 | 26 |
| 2006 | 18 |
| 2007 | 17 |
| 2008 | 19 |
| 2009 | 29 |
| 2010 | 53 |
| 2011 | 120 |
| 2012 | 125 |
| 2013 | 90 |
| 2014 | 56 |
| 2015 | 73 |
| 2016 | 71 |
| 2017 | 117 |
| 2018 | 109 |
| 2019 | 705 |
| 2020 | 954 |
| 2021 | 1,056 |
| 2022 | 1,134 |
| 2023 | 1,333 |
| 2024 | 1,333 |
| 2025 | 1,427 |
| 2026 | 1,078 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,044,192 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| lymphocyte count decreasedSignal | 507 | 62.3 | 57.2 | 29,665 |
| lymphopeniaSignal | 238 | 36.1 | 31.8 | 7,957 |
| multiple sclerosis relapseSignal | 494 | 15.3 | 14.0 | 6,569 |
| multiple sclerosisSignal | 270 | 12.0 | 10.6 | 2,696 |
| white blood cell count decreasedSignal | 376 | 7.3 | 6.6 | 2,057 |
| febrile neutropeniaSignal | 218 | 7.0 | 6.1 | 1,105 |
| urinary tract infectionSignal | 288 | 3.6 | 3.2 | 533 |
| pneumoniaSignal | 418 | 2.7 | 2.5 | 462 |
| headacheSignal | 713 | 2.4 | 2.2 | 599 |
| fatigueSignal | 848 | 2.3 | 2.2 | 645 |
| pyrexia | 294 | 1.8 | 1.6 | 104 |
| asthenia | 252 | 1.4 | 1.3 | 31 |
| nausea | 437 | 1.2 | 1.1 | 10 |
| off label use | 339 | 0.8 | 0.7 | 14 |
| drug ineffective | 309 | 0.5 | 0.4 | 170 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.